Figure 1: ANGPTL2 expression is increased in stressed cardiomyocytes.

(a–c) Representative western blot and quantitation of ANGPTL2 protein in hearts from WT mice 6 weeks after TAC or sham surgery (n=5 per group) (a) and 2 weeks after Angiotensin II (Ang II) or vehicle treatment (n=8 per group) (b). Analysis of ANGPTL2 and GFP protein from GFP⁺ cardiomyocytes and GFP⁻ non-cardiomyocytes from Myh6-EGFP Tg mice (n=3 per group) (c). Hsc70 served as a loading control. Normalized values from controls (a,b) or GFP⁺ cardiomyocytes (c) were set to 1. (d,e) Quantitative RT-PCR analysis of Angptl2 expression in GFP⁺ and GFP^– cells 6 weeks after TAC or sham surgery (d) and 2 weeks after Ang II or vehicle treatment (e) (n=3 per group). Values for respective controls were set to 1. (f,g) Relative ANGPTL2 transcript (f) and protein (g) levels in NRCMs assessed 6 or 12 h after Ang II (left in f,g) or Iso (right in f) treatment, with or without cyclosporine A (CsA) treatment. Values before treatment were set to 1. n=4–8 per group. (h) Relative ANGPTL2 transcript levels in NRCMs 8 h after Ang II treatment, with or without xestospongin C (Xes C) treatment. Values from control NRCMs were set to 1. n=8 per group. (i) Relative Angptl2 transcript levels in NRCMs overexpressing constitutively active NFAT (CA-NFAT). Values from control NRCMs were set to 1. n=3 per group. Data are means±s.e.m. Statistical significance was determined by Student’s t test (a–e and i) or one-way ANOVA (f–h). *P<0.05, **P<0.01, ^†P<0.001 between groups.